



## ASX Announcement

1 April 2022

# Executive Director Agreement

---

**Invex Therapeutics Ltd (Invex, ASX: IXC, or the Company)** a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure today announces the completion of a new Executive Director contract with Dr Tom Duthy, effective 1 April 2022.

Dr Duthy's Executive Director salary will comprise Director fees of \$50,000 per annum and consulting fees of \$130,000 excluding GST. Either party has the right to terminate the agreement with 90 days' written notice. Dr Duthy is not entitled to any short-term incentives, except as incurred in normal operations of the business. He is eligible for long term incentives through participation in the Invex Employee Securities Incentive Plan, subject to shareholder approval as required. The material terms of the contract are presented in accordance with Listing Rule 3.16.4.

Dr Duthy is primarily responsible for Invex's corporate activities within Australia, including corporate governance, ASX requirements and investor relations while also providing advice relating to strategy, structuring and corporate development.

***This release dated 1 April 2022 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.***

**ENDS**

---

### For more information, please contact:

#### Company/Investors

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

#### Media

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter **@InvexThera\_ASX**

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).

## About Idiopathic Intracranial Hypertension (IIH)

---

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

## About Presendin™

---

Presendin™ is a once per week, sub-cutaneous, sustained release (SR) Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010). In September 2021 Invex entered into an exclusive collaboration, manufacturing and supply agreement with Peptron for Presendin™ in IIH for all major markets, with the exception of South Korea.

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which is currently approved for the treatment of type 2 diabetes. In 2017, Invex received orphan drug designation for Exenatide in IIH from the US Food and Drug Administration and European Medicines Agency.